2003, May
|
-
|
GlaxoSmithKline
|
Reported to FDA increased suicidal behaviour associated with paroxetine
|
2003, June
|
U.K.
|
MHRAa
|
Paroxetine contraindicated in <18 s
|
2003, September
|
U.K.
|
MHRA
|
Venflaxine contraindicated in <18 s
|
2003, October
|
U.S.
|
FDAb
|
Advice paper published stating preliminary data suggests increased suicidal behaviour associated with SSRIs
|
2003, December
|
U.K.
|
MHRA
|
Contraindicate all SSRIs in <18 s apart from Prozac (fluoxetine)
|
2003, December
|
Ireland
|
IMBc
|
Endorses MHRA warning for Ireland
|
2004, February
|
U.S.
|
FDA
|
Commissioned advisory committee
|
2004, October
|
U.S.
|
FDA
|
Issued black box warning relating to all anti-depressants <18 s
|
2005, August
|
Europe
|
EMEAd
|
Issued warning against SSRIs in <18 s
|
2005, November
|
Ireland
|
IMB
|
Reissued warning and updated label guidelines
|
2007, May
|
U.S.
|
FDA
|
Increased age of risk of SSRIs to 24 years
|
2008, September
|
Ireland
|
IMB
|
Warnings adapted up to age 25
|